Prediction market platform Kalshi announced Thursday it will begin offering markets for the outcomes of clinical trials and FDA regulatory reviews. This initiative aims to make drug-development odds publicly available for the first time, according to Reuters.
What Happened
On Thursday, July 16, 2026, prediction market platform Kalshi stated its intention to commence taking bets on the outcomes of clinical trials and decisions from the U.S. Food and Drug Administration (FDA) (Reuters). This development will reportedly make drug-development odds public for the first time, as stated by Kalshi and reported by Reuters.
The introduction of these new markets by Kalshi is part of a pilot program for biotech prediction markets, as detailed in a report by Kalshi itself. This program focuses on events like clinical trial outcomes and FDA regulatory reviews (Kalshi launches biotech prediction markets pilot program).
Key Details
- Kalshi will allow bets on both clinical trial outcomes and FDA regulatory decisions (Reuters, SRN News).
- This initiative aims to publicly disclose drug-development odds, a first for the industry (Reuters, Pharmalittle).
- The new markets are part of a pilot program launched by Kalshi focusing on biotech prediction markets (Kalshi launches biotech prediction markets pilot program).
Why It Matters
The introduction of these markets by Kalshi marks a significant shift in the accessibility of drug development data. By allowing bets on clinical trial and FDA review outcomes, Kalshi is making previously less transparent drug-development odds public (Reuters, Pharmalittle). This move provides a new mechanism for assessing the potential success or failure rates of medicinal products, which could be relevant for B2B operators, regulators, and industry analysts monitoring pharmaceutical development pipelines.
Originally reported by ReutersPublished
Sources & References
Primary source
- Reutersreuters.com